

| Name of the Issue: Mankind Pharma Limited | |
|---|---|
| 1 | Type of Issue Initial Public Offer |
| 2 | Issue Size (Rs. Mn) 43263.55* |
| <i>*Source: Prospectus dated April 28, 2023</i> | |
| 3 | Grade of issue along with name of the rating agency |
| | Name NA |
| | Grade NA |

| | |
|---|---|
| 4 | Subscription Level (Number of times) 15.4631* |
| <i>* excluding Anchor Investor Portion and after removing multiple and duplicate bids</i> | |
| <i>Source: Minutes for basis of allotment dated May 03, 2023</i> | |

| 5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges | |
|---|---------------|
| Particulars | % |
| (i) On Allotment ** | 5.28% |
| (ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2023) | 4.18% |
| (iii) at the end of 1st FY (March 31, 2024) | 21.01% |
| (iv) at the end of 2nd FY (March 31, 2025) * | Not Available |
| (v) at the end of 3rd FY (March 31, 2026) * | Not Available |
| <i>**Basis of Allotment (excluding pre-issue QIB holding)</i> | |
| <i>* QIB Holding not disclosed as reporting for relevant period has not been completed.</i> | |

| 6 Financials of the issuer | | Rs. In lacs | | |
|---|------------------------|-------------------------|-------------------------|--|
| Parameters | 1st FY (March 31,2024) | 2nd FY (March 31,2025)* | 3rd FY (March 31,2026)* | |
| Income from operations | 10,33,477.46 | Not Available | Not Available | |
| Net Profit/(Loss) for the period | 1,94,177.17 | Not Available | Not Available | |
| Paid-up equity share capital | 4,005.88 | Not Available | Not Available | |
| Reserves excluding revaluation reserves | 9,32,302.93 | Not Available | Not Available | |
| <i>* Financials not available as reporting for the relevant years has not been completed.</i> | | | | |

| 7 Trading Status | |
|---|-------------------|
| Particulars | Status |
| (i) at the end of 1st FY (March 31, 2024) | Frequently Traded |
| (ii) at the end of 2nd FY (March 31, 2025)* | Not Available |
| (iii) at the end of 3rd FY (March 31, 2026)* | Not Available |
| <i>* Trading status not disclosed as the relevant fiscal years have not been completed.</i> | |

| 8 Change in Directors of Issuer from the disclosures in the offer document | | | | | | | |
|--|---|---|---|---|---------------|---------------|--|
| Particulars | Name of Director | Appointed / Resigned | | | | | |
| (i) at the end of 1st FY (March 31, 2024) | No change | NA | | | | | |
| (ii) at the end of 2nd FY (March 31, 2025)* | Not Available | Not Available | | | | | |
| (iii) at the end of 3rd FY (March 31, 2026)* | Not Available | Not Available | | | | | |
| <i>* Changes in Directors of Issuer not updated as the relevant financial years have not been completed</i> | | | | | | | |
| 9 Status of implementation of project/ commencement of commercial production | | | | | | | |
| (i) as disclosed in the offer document | Not applicable | | | | | | |
| (ii) Actual implementation | Not applicable | | | | | | |
| (iii) Reasons for delay in implementation, if any | Not applicable | | | | | | |
| 10 Status of utilization of issue proceeds | | | | | | | |
| (i) as disclosed in the offer document | Not applicable | | | | | | |
| (ii) Actual implementation | Not applicable | | | | | | |
| (iii) Reasons for delay in implementation, if any | Not applicable | | | | | | |
| 11 Comments of monitoring agency, if applicable | | | | | | | |
| (i) Comments on use of funds | Not applicable | | | | | | |
| (ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document | Not applicable | | | | | | |
| (iii) Any other reservations expressed by the monitoring agency about the end use of funds | Not applicable | | | | | | |
| 12 Pricing Data | | | | | | | |
| Designated Stock Exchange | NSE | | | | | | |
| Issue Price (Rs.) | 1080.00 | | | | | | |
| Listing Date | May 09, 2023 | | | | | | |
| Price parameters | At close of listing day- May 09, 2023 | Close of 30th calendar day from listing day | Close of 90th calendar day from listing day | As at the end of the 1st FY after the listing of the issue (31st March,2024) | | | |
| | | | | Closing price | High | Low | |
| Market Price | 1,430.00 | 1,486.2 | 1,803.5 | 2,300.8 | 2,336.4 | 1,322.7 | |
| Nifty 50* | 18,265.95 | 18,726.4 | 19,597.3 | 22,326.9 | 22,493.6 | 17,398.1 | |
| Price parameters | As at the end of the 2nd FY after the listing of the issue (31st March,2025) ⁽¹⁾ | | | As at the end of the 3rd FY after the listing of the issue (31st March,2026) ⁽¹⁾ | | | |
| | Closing price | High | Low | Closing price | High | Low | |
| Market Price | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | |
| Nifty 50* | Not Available | Not Available | Not Available | Not Available | Not Available | Not Available | |

* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

| Accounting ratio | Face Value per share (Rs.) | As disclosed in offer document* | At the end of 1st FY (March 31,2024) | At the end of 1st FY (March 31,2025)** | At the end of 1st FY (March 31,2026)** | | |
|---|---|---------------------------------|--------------------------------------|--|--|---------------|---------------|
| EPS (Diluted) | Company | | | | | | |
| | <i>Consolidated</i> | 1 | 35.78 | 47.68 | Not Available | Not Available | |
| | Peer Group: | | | | | | |
| | <i>Sun Pharmaceuticals Industries Limited</i> | 1 | 13.60 | 39.9 | Not Available | Not Available | |
| | <i>Cipla Limited</i> | 2 | 31.17 | 51.01 | Not Available | Not Available | |
| | <i>Zydus Lifesciences Limited</i> | 1 | 43.83 | 38.14 | Not Available | Not Available | |
| | <i>Torrent Pharmaceutical Limited</i> | 5 | 22.97 | 48.94 | Not Available | Not Available | |
| | <i>Alkem Laboratories</i> | 2 | 137.63 | 150.19 | Not Available | Not Available | |
| | <i>JB Chemicals & Pharmaceuticals Limited</i> | 2 | 49.82 | 34.85 | Not Available | Not Available | |
| | <i>Eris Lifesciences Limited</i> | 1 | 29.88 | 28.79 | Not Available | Not Available | |
| | <i>Ipca Laboratories Limited</i> | 2 | 34.85 | 21.57 | Not Available | Not Available | |
| | <i>Abbott India Limited</i> | 10 | 375.86 | 565.28 | Not Available | Not Available | |
| | <i>Glaxosmithkline Pharmaceuticals Limited</i> | 10 | 100.04 | 34.83 | Not Available | Not Available | |
| | <i>Dabur India Limited</i> | 1 | 9.81 | 10.38 | Not Available | Not Available | |
| | <i>Procter & Gamble Health Limited</i> | 10 | 116.00 | Not Available | Not Available | Not Available | |
| | <i>Zydus Wellness Limited</i> | 10 | 48.54 | 41.94 | Not Available | Not Available | |
| | Industry Avg | | 78.00 | 88.82 | Not Available | Not Available | |
| | P/E | Company | | | | | |
| | | <i>Consolidated</i> | 1 | 30.18 | 48.25 | Not Available | Not Available |
| Peer Group: | | | | | | | |
| <i>Sun Pharmaceuticals Industries Limited</i> | | 1 | 71.54 | 40.62 | Not Available | Not Available | |
| <i>Cipla Limited</i> | | 2 | 28.18 | 29.35 | Not Available | Not Available | |
| <i>Zydus Lifesciences Limited</i> | | 1 | 10.95 | 26.41 | Not Available | Not Available | |
| <i>Torrent Pharmaceutical Limited</i> | | 5 | 66.25 | 53.14 | Not Available | Not Available | |
| <i>Alkem Laboratories</i> | | 2 | 23.03 | 32.90 | Not Available | Not Available | |
| <i>JB Chemicals & Pharmaceuticals Limited</i> | | 2 | 39.48 | 47.36 | Not Available | Not Available | |
| <i>Eris Lifesciences Limited</i> | | 1 | 19.1 | 29.29 | Not Available | Not Available | |
| <i>Ipca Laboratories Limited</i> | | 2 | 22.38 | 57.37 | Not Available | Not Available | |
| <i>Abbott India Limited</i> | | 10 | 56.19 | 47.98 | Not Available | Not Available | |
| <i>Glaxosmithkline Pharmaceuticals Limited</i> | | 10 | 57.03 | 55.89 | Not Available | Not Available | |
| <i>Dabur India Limited</i> | | 1 | 54.55 | 50.40 | Not Available | Not Available | |
| <i>Procter & Gamble Health Limited</i> | | 10 | 42.27 | Not Available | Not Available | Not Available | |
| <i>Zydus Wellness Limited</i> | | 10 | 31.11 | 35.18 | Not Available | Not Available | |
| Industry Avg | | | 40.16 | 42.16 | Not Available | Not Available | |

| | Company | | | | | | |
|---|---|---|----------|---------------|---------------|---------------|---------------|
| RoNW | Consolidated | 1 | 23.29% | 20.74% | Not Available | Not Available | |
| | Peer Group: | | | | | | |
| | <i>Sun Pharmaceuticals Industries Limited</i> | 1 | 6.82% | 15.04% | Not Available | Not Available | |
| | <i>Cipla Limited</i> | 2 | 12.08% | 15.55% | Not Available | Not Available | |
| | <i>Zydus Lifesciences Limited</i> | 1 | 26.40% | 19.46% | Not Available | Not Available | |
| | <i>Torrent Pharmaceutical Limited</i> | 5 | 13.06% | 24.15% | Not Available | Not Available | |
| | <i>Alkem Laboratories</i> | 2 | 19.05% | 17.57% | Not Available | Not Available | |
| | <i>JB Chemicals & Pharmaceuticals Limited</i> | 2 | 18.06% | 18.90% | Not Available | Not Available | |
| | <i>Eris Lifesciences Limited</i> | 1 | 21.28% | 15.35% | Not Available | Not Available | |
| | <i>Ipca Laboratories Limited</i> | 2 | 16.10% | 8.36% | Not Available | Not Available | |
| | <i>Abbott India Limited</i> | 10 | 28.32% | 32.48% | Not Available | Not Available | |
| | <i>Glaxosmithkline Pharmaceuticals Limited</i> | 10 | 63.64% | 33.19% | Not Available | Not Available | |
| | <i>Dabur India Limited</i> | 1 | 20.75% | 18.36% | Not Available | Not Available | |
| | <i>Procter & Gamble Health Limited</i> | 10 | 31.23% | Not Available | Not Available | Not Available | |
| | <i>Zydus Wellness Limited</i> | 10 | 6.38% | 4.98% | Not Available | Not Available | |
| | Industry Avg | | 21.78% | 18.62% | Not Available | Not Available | |
| | NAV per share | Company | | | | | |
| | | Consolidated | 10 | 31.76 | 233.73 | Not Available | Not Available |
| | | Peer Group: | | | | | |
| | | <i>Sun Pharmaceuticals Industries Limited</i> | 1 | 200.10 | 265.35 | Not Available | Not Available |
| <i>Cipla Limited</i> | | 2 | 258.32 | 330.78 | Not Available | Not Available | |
| <i>Zydus Lifesciences Limited</i> | | 1 | 166.05 | 197.07 | Not Available | Not Available | |
| <i>Torrent Pharmaceutical Limited</i> | | 5 | 175.89 | 202.58 | Not Available | Not Available | |
| <i>Alkem Laboratories</i> | | 2 | 722.44 | 862.46 | Not Available | Not Available | |
| <i>JB Chemicals & Pharmaceuticals Limited</i> | | 2 | 240.83 | 188.37 | Not Available | Not Available | |
| <i>Eris Lifesciences Limited</i> | | 1 | 140.39 | 190.12 | Not Available | Not Available | |
| <i>Ipca Laboratories Limited</i> | | 2 | 216.47 | 249.59 | Not Available | Not Available | |
| <i>Abbott India Limited</i> | | 10 | 1,327.00 | 1,740.71 | Not Available | Not Available | |
| <i>Glaxosmithkline Pharmaceuticals Limited</i> | | 10 | 157.19 | 104.93 | Not Available | Not Available | |
| <i>Dabur India Limited</i> | | 1 | 47.41 | 55.68 | Not Available | Not Available | |
| <i>Procter & Gamble Health Limited</i> | | 10 | 371.39 | Not Available | Not Available | Not Available | |
| <i>Zydus Wellness Limited</i> | | 10 | 761.26 | 841.95 | Not Available | Not Available | |
| Industry Avg | | | 368.06 | 435.80 | Not Available | Not Available | |

Notes

* Sourced from Prospectus dated April 28, 2023.

**Not available as the relevant fiscal years have not been completed / information not disclosed

14 Any other material information

| Particulars | Date | Remarks |
|----------------|------|---------|
| Not Applicable | | |

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com